PD1/PDL1 inhibitors have shown efficacy in relapsed/refractory NKTCL, with overall response rate (ORR) being 38%-75% and CR rate being 24%-35.9% (3, 4). Here, CD274 is linked to extranodal nasal NK/T cell lymphoma.